These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28124399)

  • 1. Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
    Bezin J; Groenwold RH; Ali MS; Lassalle R; Robinson P; de Boer A; Moore N; Klungel OH; Pariente A
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):285-293. PubMed ID: 28124399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting.
    Bezin J; Klungel OH; Lassalle R; Dureau-Pournin C; Moore N; Pariente A
    Clin Pharmacol Ther; 2018 Jun; 103(6):1038-1046. PubMed ID: 28875506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
    Bezin J; Pariente A; Lassalle R; Dureau-Pournin C; Abouelfath A; Robinson P; Moore N; Droz-Perroteau C; Fourrier-Reglat A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):429-36. PubMed ID: 24271648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome.
    Wang CY; Lin ZF; Lee CM; Tsai YW; Huang TY; Shen LJ; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):229-238. PubMed ID: 28067454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medication adherence to secondary prevention for coronary artery disease].
    Rossi E; Perman G; Michelangelo H; Alonzo CB; Brescacin L; Kopitowski KS; Navarro Estrada JL
    Medicina (B Aires); 2014; 74(2):99-103. PubMed ID: 24736251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors.
    Gunnell AS; Hung J; Knuiman MW; Nedkoff L; Gillies M; Geelhoed E; Hobbs MS; Katzenellenbogen JM; Rankin JM; Ortiz M; Briffa TG; Sanfilippo FM
    Cardiovasc Ther; 2016 Dec; 34(6):423-430. PubMed ID: 27489053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases.
    Neumann A; Maura G; Weill A; Alla F; Danchin N
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004356. PubMed ID: 29653999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 10. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
    J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function.
    Khedri M; Szummer K; Carrero JJ; Jernberg T; Evans M; Jacobson SH; Spaak J
    Eur J Prev Cardiol; 2017 May; 24(7):724-734. PubMed ID: 28195517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34).
    Chan D; Doughty RN; Lund M; Lee M; Kerr AJ
    Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan.
    Lin CF; Gau CS; Wu FL; Hsiao FY; Bai CH; Shen LJ
    Clin Ther; 2011 Sep; 33(9):1120-31. PubMed ID: 21872930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization.
    Albani S; Fabris E; Doimo S; Barbati G; Perkan A; Merlo M; Gatti G; Di Lenarda A; Van't Hof AWJ; Maras P; Sinagra G
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):195-201. PubMed ID: 29846559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating mortality in survivors of the acute coronary syndrome by the 4-drug score.
    Kopel E; Klempfner R; Goldenberg I; Schwammenthal E
    Cardiology; 2014; 127(2):83-9. PubMed ID: 24280900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
.
    Kang HB; Choi M; Yoon SG; Cho YS; Je NK
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
    Thompson PL; Thompson AG; Judkins C
    Med J Aust; 2014 Nov; 201(10):S100-5. PubMed ID: 25390495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.